Rattled by setbacks, Celgene turns to ex-Merck R&D star Alise Reicin to repair its damaged development rep
At a time when the executive crew at Celgene has rattled investors with a series of setbacks on clinical development, the big biotech is reorganizing its leadership on drug development and turning to a former Merck R&D star to lead the way out of the wilderness.
Alise Reicin, who played a major role in the big development campaign for Merck’s Keytruda, is being placed in charge of the critical mid- to late-stage development work at Celgene, where it’s been experiencing its biggest problems.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.